Last news
Sungrow and Smart Commercial Solar Partner to Build Sustainable Energy Infrastructure for Leading Aged Care Provider, Opal HealthCare

Sungrow and Smart Commercial Solar Partner to Build Sustainable Energy Infrastructure for Leading Aged Care Provider, Opal HealthCare

SYDNEY, Nov. 28, 2024 /PRNewswire/ -- Sungrow, the global leading PV inverter and energy storage system provider, announced that its C&I solar solutions were selected by Smart Commercial Solar for their national Opal HealthCare clean energy...

Taiwan Tourism Administration Promotes Muslim-Friendly Tourism

Taiwan Tourism Administration Promotes Muslim-Friendly Tourism

Crown Coast Tourism Union Joins Forces with the Great Northeast Tourism Union for Networking Event TAIPEI, Nov. 28, 2024 /PRNewswire/ -- According to international reports, the growing global Muslim population and evolving demographic trends...

Jiangsu in Focus: Bridging History and the Future Through High-Quality Development

Jiangsu in Focus: Bridging History and the Future Through High-Quality Development

NANJING, China, Nov. 27, 2024 /PRNewswire/ -- "This is my first time in Jiangsu, and I loved the beautiful rural villages," Helena Kočova, a journalist from Czech Republic's Naše Pravda, said during her trip in Jiangsu. "The innovative approach to...

Gravity Announces Global Release of Tokyo Psychodemic

Gravity Announces Global Release of Tokyo Psychodemic

Available now on PlayStation®4, PlayStation®5, and Nintendo Switch™, with updated language support on Steam®. Digital versions are available for immediate download and play through the PlayStation Store and Nintendo eShop. SEOUL, South Korea, Nov....

Everest Medicines Announces NEFECON®, the World's First Approved Treatment for IgA Nephropathy, is Included in China's National Reimbursement Drug List

Everest Medicines Announces NEFECON®, the World's First Approved Treatment for IgA Nephropathy, is Included in China's National Reimbursement Drug List

SHANGHAI, Nov. 28, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today...

Antengene Announces XPOVIO®'s New Indication Included in 2024 China National Reimbursement Drug List, Making the Drug More Accessible to DLBCL Patients in the Country

Antengene Announces XPOVIO®'s New Indication Included in 2024 China National Reimbursement Drug List, Making the Drug More Accessible to DLBCL Patients in the Country

SHANGHAI and HONG KONG, Nov. 28, 2024 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing...

ASSEMBLY ELEVATES VIVIAN MOK TO SVP & MANAGING DIRECTOR FOR NORTH ASIA

ASSEMBLY ELEVATES VIVIAN MOK TO SVP & MANAGING DIRECTOR FOR NORTH ASIA

Mok will be pivotal in solidifying Assembly's proposition and accelerating the agency's growth in North Asia SEOUL, South Korea, Nov. 28, 2024 /PRNewswire/ -- Assembly, a leading global omnichannel media agency, announced today the promotion of...

Innovent Announces First-Time Inclusion of SINTBILO® and New Indication for Olverembatinib in China's National Reimbursement Drug List

Innovent Announces First-Time Inclusion of SINTBILO® and New Indication for Olverembatinib in China's National Reimbursement Drug List

SAN FRANCISCO and SUZHOU, China, Nov. 28, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of...

menu
menu